in Health care
USFDA nod to Roche’s Polivy in combination with R-CHP for certain types of previously untreated diffuse large B-cell lymphoma
Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an […] More
